<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: It is unclear if <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (MS) is equal to type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (DM) in predicting <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) risk and mortality, and its prognostic value compared to Framingham risk model is controversial </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed mortality, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk and prevalence in patients with DM and those without DM who met National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) MS criteria compared to patients without DM or MS </plain></SENT>
<SENT sid="2" pm="."><plain>We analysed which component(s) of NCEP MS criteria had greatest predictive value for mortality </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Retrospective cohort analysis of 1189 DM, 1241 MS (fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> &lt; 126 mg/dl and &gt; or =3 components NCEP-ATP III criteria) and 3023 non-DM/non-MS patients presented for baseline visit to Preventive Cardiology clinic between 1995 and 2006, whose subsequent vital status was determined for a median of 5.2 years </plain></SENT>
<SENT sid="4" pm="."><plain>The association with mortality was determined by Cox proportional hazards models </plain></SENT>
<SENT sid="5" pm="."><plain>The incremental predictive value of MS components was performed by concordance indexes </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS AND CONCLUSION: DM group had highest mortality and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> prevalence vs. MS and non-DM/non-MS groups respectively (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; or = 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with MS criteria had increased <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> prevalence and 1.5-fold increased mortality vs. non-DM/non-MS group (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.02) </plain></SENT>
<SENT sid="8" pm="."><plain>In NCEP MS criteria, only fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> significantly predicted mortality in MS group (p = 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>MS criteria predicted <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> prevalence in a parallel manner to Framingham risk score assessment </plain></SENT>
<SENT sid="10" pm="."><plain>In a cohort of patients at high risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> whose risk factors are being treated, presence of <z:mp ids='MP_0002055'>diabetes</z:mp> in addition to plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> within NCEP MS criteria strongly predicts <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
</text></document>